InspireMD (NYSE:NSPR) is now covered by analysts at Maxim Group. They set a "buy" rating and a $6.00 price target on the stock.
InspireMD Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
InspireMD Announces Publication of the C-GUARDIANS Pivotal Trial Manuscript in the Journal of the American College of Cardiology (JACC)
InspireMD (NASDAQ:NSPR) shareholders have endured a 81% loss from investing in the stock five years ago [Yahoo! Finance]
Landmark CREST-2 Study Published in the New England Journal of Medicine Highlights the Benefits of Carotid Artery Stenting